Actively Recruiting
Single and Multiple Ascending Dose Study of AMG 513 in Participants With Obesity
Led by Amgen · Updated on 2026-02-13
80
Participants Needed
5
Research Sites
107 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The primary objective of this study is to assess the safety and tolerability of AMG 513 after single and multiple doses.
CONDITIONS
Official Title
Single and Multiple Ascending Dose Study of AMG 513 in Participants With Obesity
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults aged 18 to 65 years at the time of informed consent
- Body mass index (BMI) of 30.0 to 40.0 kg/m² for Part A and 27.0 to 40.0 kg/m² for Part B
- Female participants must be of non-childbearing potential
You will not qualify if you...
- History or clinical evidence of diabetes mellitus, including hemoglobin A1c ≥ 6.5% or fasting glucose ≥ 126 mg/dL at screening
- Triglycerides ≥ 5.65 mmol/L (500 mg/dL) at screening
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 5 locations
1
Anaheim Clinical Trials
Anaheim, California, United States, 92801
Actively Recruiting
2
Carilion Medical Center
Lake Forest, California, United States, 92630
Actively Recruiting
3
Fomat Medical Research
Oxnard, California, United States, 93030
Actively Recruiting
4
Translational Clinical Research LLC
Aventura, Florida, United States, 33180
Actively Recruiting
5
Clinical Pharmacology of Miami, LLC
Miami, Florida, United States, 33172
Actively Recruiting
Research Team
A
Amgen Call Center
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here